Jacobs Awarded Additional Contract from Bristol-Myers Squibb
May 19 2015 - 7:45AM
Business Wire
Delivering State-of-the-Art Large-Scale
Biologics Manufacturing Facility in Ireland
Jacobs Engineering Group Inc. (NYSE:JEC) announced today that it
received a contract from Bristol-Myers Squibb Company to provide
construction management services for a new large-scale biologics
manufacturing facility in Cruiserath, County Dublin, Ireland.
Jacobs is also providing architectural and engineering services
for the facility, which is being built to produce multiple
therapies for the company’s robust and growing portfolio of
approved and investigational biologic medicines, and to increase
Bristol-Myers Squibb’s biologics manufacturing capacity. The new
facility is expected to include multiple large scale bioreactors, a
purification area, as well as office and laboratory space.
Bristol-Myers Squibb’s Board of Directors has approved initial
funding that will support the first phase of the project, with the
full cost of the facility expected to be finalized in the second
half of 2015.
In making the announcement, Jacobs Group Vice President Chris
Nagel stated, “We are excited to provide construction management
services to Bristol-Myers Squibb, especially since our team is
already mobilized and engaged in this project. The continuity and
knowledge we bring, having already provided architectural and
engineering services, is a tremendous benefit in bringing this
project to fruition.”
The facility is estimated to be operational in 2019.
Jacobs, one of the world's largest and most diverse providers of
technical professional and construction services, consistently
delivers award-winning pharmaceutical and biotechnology projects
worldwide.
Statements made in this release that are not based on historical
fact are forward-looking statements. We base these forward-looking
statements on management’s current estimates and expectations as
well as currently available competitive, financial and economic
data. Forward-looking statements, however, are inherently
uncertain. There are a variety of factors that could cause business
results to differ materially from our forward-looking
statements. For a description of some of the factors which may
occur that could cause actual results to differ from our
forward-looking statements please refer to our 2014 Form 10-K, and
in particular the discussions contained under Items 1 - Business,
1A - Risk Factors, 3 - Legal Proceedings, and 7 - Management's
Discussion and Analysis of Financial Condition and Results of
Operations. We do not undertake to update any forward-looking
statements made herein.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150519005437/en/
Jacobs Engineering Group Inc.Michelle Jones, 626-578-6968
Jacobs Engineering (NYSE:JEC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Jacobs Engineering (NYSE:JEC)
Historical Stock Chart
From Jul 2023 to Jul 2024